Company Overview and News
Document UNITED STATES
Document SCHEDULE 14A (Rule 14a-101)
Document SCHEDULE 14A
Alcoa Corp (NYSE:AA) has posted its numbers, and the first-quarter earnings season is unofficially underway. And, if the company really is the tone-setter for earnings reports, we have good reason to be excited.the aluminum company topped its earnings expectations, and AA stock advanced 4% in response.
BAC AAI AA.PR CENX AA.PRB KALU NFLX AA
CHICAGO, April 16, 2018 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ:CENX) will report first quarter 2018 earnings on Thursday, May 3, 2018 after the close of market trading. The news release will be issued through GlobeNewswire.
When President Trump threw Rusal CEO Oleg Deripaska under the bus last Friday, commodities traders and investors began to calculate how much damage the Russian aluminum giant would suffer. The answer appears to be “a lot.”
AAI RTPPF RIO RIO RIO AA.PR RTNTF CENX AA.PRB AA
The week started off strong out of the gate on Monday in the wake of Friday's post-payroll rally, but the momentum quickly faded, leaving the S&P 500 down four consecutive days as of Thursday's close. If it closes in the red again Friday, it will be the longest losing streak in over 16 months going back October 31st, 2016. We dug into the details of the recent data, and in this week's edition, we point out some things that just aren't jiving.
DLTR TGT KR COST CENX BIG BA DWDP WMT
Century Aluminum Co. (NASDAQ: CENX) is one of the great American metals companies that should be set to win if steel and aluminum tariffs do not turn into an all-out trade war. There are of course risks, particularly if steel and aluminum were just the start. Wall Street thinks Century Aluminum is now in the sweet spot.
7h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
8h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET